medalphabetМедицинский алфавитMedical alphabet2078-56312949-2807ООО «Альфмед»10.33667/2078-5631-2020-38-41-45medalphabet-1890Research ArticleСтатьиМолекулярные механизмы развития костных метастазов (обзор литературы)Molecular mechanisms of osteotropic cancer metastasis (literature review)КовалеваИ. В.KovalyovaI. V.

лаборант-исследователь лаборатории биохимии опухолей

г. Томск

Tomsk

СпиринаЛ. В.SpirinaL. V.

д.м.н., проф. кафедры биохимии и молекулярной биологии; в.н.с.

г. Томск

Tomsk

ГорбуновА. К.GorbunovA. K.

м.н.с. отделения общей онкологии

г. Томск

Tomsk

УсынинЕ. А.UsyninE. A.

д.м.н., зав. отделением общей онкологии

г. Томск

Tomsk

НИИ онкологии ФГБУ «Томский национальный исследовательский медицинский центр» Российской академии наукРоссияTomsk National Research Medical Centre of the Russian Academy of SciencesRussian FederationФГАОУ ВО «Сибирский государственный медицинский университет» Минздрава России; НИИ онкологии ФГБУ «Томский национальный исследовательский медицинский центр» Российской академии наукРоссияSiberian State Medical University; Tomsk National Research Medical Centre of the Russian Academy of SciencesRussian FederationФГАОУ ВО «Сибирский государственный медицинский университет» Минздрава РоссииРоссияSiberian State Medical UniversityRussian Federation202023012021038Диагностика и онкотерапия (4)4145Copyright © Ковалева И.В., Спирина Л.В., Горбунов А.К., Усынин Е.А., 20212021Ковалева И.В., Спирина Л.В., Горбунов А.К., Усынин Е.А.Kovalyova I.V., Spirina L.V., Gorbunov A.K., Usynin E.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-alphabet.com/jour/article/view/1890

Появление метастазов является одной из ведущих причин летального исхода при раке предстательной железы, раке молочной железы и почечно-клеточном раке, представляющих серьезную медицинскую проблему населения. В этой связи особый интерес для изучения представляет костная локализация вторичной опухоли. Подобная тропность обусловлена молекулярными особенностями опухолевых клеток, которые подвержены аттрактированию факторами и молекулами, выделяемыми микроокружением костной ткани. Растущая в кости метастатическая ниша разрушает ее, вызывая сильную боль, переломы и нарастающую гиперкальциемию. Тяжелые клинические проявления, тянущие за собой высокую частоту осложнений, а также отсутствие эффективных стандартов терапии метастатического рака делают актуальным изучение молекулярного механизма их возникновения и прогрессирования.

Bone is a frequent site of metastasis for a wide range of cancer types. The most common cancers that often spread to bone are prostate cancer, breast cancer and renal cell carcinoma. In this regard, the preferential bone localization of tumor cells is determined by their molecular features and attraction by bone microenvironment. Metastatic niche growth destroys the bone, and as a result, patients are suffering from symptoms also known as skeletal-related events: severe pain, fractures, progressive hypercalcemia, resulting in high rates of cancer-dependent complications. Lack in effective guidelines and management procedures in metastatic cancer therapy highlights the issues of molecular mechanism investigation. Here, we discuss about bone microenvironment and how it impacts to tumor growth, cancer progression and dormancy.

костные метастазыметастатический ракрак предстательной железырак молочной железырак почкиbone metastasismetastatic cancerprostate cancerbreast cancerrenal cell carcinomaReferencesКаприн А. Д., Старинский В. В., Петрова Г. В. Злокачественные новообразования в России в 2018 году (заболеваемость и смертность). М.: МНИОИ им. П. А. Герцена филиал ФГБУ «НМИЦ радиологии» Минздрава России. 2019; C. 250. [Kaprin A.D., Starinsky V.V., Petrova G.V. Condition of the oncology aid to the population of Russia in 2018. M. edition: P. Hertsen Moscow Oncology Research Center, branch of the FSBI NMRRC of the Ministry of Health of the Russian Federation. 2019; p. 250 (In Rus)]Каприн А. Д., Старинский В. В., Петрова Г. В. Злокачественные новообразования в России в 2018 году (заболеваемость и смертность). М.: МНИОИ им. П. А. Герцена филиал ФГБУ «НМИЦ радиологии» Минздрава России. 2019; C. 250. [Kaprin A.D., Starinsky V.V., Petrova G.V. Condition of the oncology aid to the population of Russia in 2018. M. edition: P. Hertsen Moscow Oncology Research Center, branch of the FSBI NMRRC of the Ministry of Health of the Russian Federation. 2019; p. 250 (In Rus)]Zhang X. Interactions between cancer cells and bone microenvironment promote bone metastasis in prostate cancer. Cancer Commun (Lond). 2019; 39 (1): 76. https://doi.org/10.1186/s40880-019-0425-1Zhang X. Interactions between cancer cells and bone microenvironment promote bone metastasis in prostate cancer. Cancer Commun (Lond). 2019; 39 (1): 76. https://doi.org/10.1186/s40880-019-0425-1Wong E. C.L., Kapoor A. Does Bone-targeted Therapy Benefit Patients with Metastatic Renal Cell Carcinoma? Transl Oncol. 2020; 13 (2): 241-244. https://doi.org/10.1016/j.tranon.2019.10.009Wong E. C.L., Kapoor A. Does Bone-targeted Therapy Benefit Patients with Metastatic Renal Cell Carcinoma? Transl Oncol. 2020; 13 (2): 241-244. https://doi.org/10.1016/j.tranon.2019.10.009Xiang L., Gilkes D. M. The Contribution of the Immune System in Bone Metastasis Pathogenesis. Int J Mol Sci. 2019; 20 (4): 999. https://doi.org/10.3390/ijms20040999Xiang L., Gilkes D. M. The Contribution of the Immune System in Bone Metastasis Pathogenesis. Int J Mol Sci. 2019; 20 (4): 999. https://doi.org/10.3390/ijms20040999Chen S. C., Kuo P.-L. Bone Metastasis from Renal Cell Carcinoma. Int J Mol Sci. 2016; 17 (6): 987. https://doi.org/10.3390/ijms17060987Chen S. C., Kuo P.-L. Bone Metastasis from Renal Cell Carcinoma. Int J Mol Sci. 2016; 17 (6): 987. https://doi.org/10.3390/ijms17060987Quayle L., Ottewell P. D., Holen I. Bone Metastasis: Molecular Mechanisms Implicated in Tumour Cell Dormancy in Breast and Prostate Cancer. Current Cancer Drug Targets. 2015; 15 (6): 469-80. https://doi.org/10.2174/1568009615666150506092443Quayle L., Ottewell P. D., Holen I. Bone Metastasis: Molecular Mechanisms Implicated in Tumour Cell Dormancy in Breast and Prostate Cancer. Current Cancer Drug Targets. 2015; 15 (6): 469-80. https://doi.org/10.2174/1568009615666150506092443Lin S.-C., Yu-Lee L.-Y., Lin S.-H. Osteoblastic Factors in Prostate Cancer Bone Metastasis. Curr Osteoporos Rep. 2018; 16 (6): 642-647. https://doi.org/10.1007/s11914-018-0480-6Lin S.-C., Yu-Lee L.-Y., Lin S.-H. Osteoblastic Factors in Prostate Cancer Bone Metastasis. Curr Osteoporos Rep. 2018; 16 (6): 642-647. https://doi.org/10.1007/s11914-018-0480-6Yang M., Liu C., Yu X. Skeletal-related adverse events during bone metastasis of breast cancer: current status. Discov Med. 2019; 27 (149): 211-220Yang M., Liu C., Yu X. Skeletal-related adverse events during bone metastasis of breast cancer: current status. Discov Med. 2019; 27 (149): 211-220Simmons J. K., Hildreth B. E., Supsavhad W., Elshafae S. M., Hassan B. B., Dirksen W.P., Toribio R.E., Rosol T.J. Animal Models of Bone Metastasis. Vet Pathol. 2015; 52 (5): 827-841. https://doi.org/10.1177/0300985815586223Simmons J. K., Hildreth B. E., Supsavhad W., Elshafae S. M., Hassan B. B., Dirksen W.P., Toribio R.E., Rosol T.J. Animal Models of Bone Metastasis. Vet Pathol. 2015; 52 (5): 827-841. https://doi.org/10.1177/0300985815586223Landgraf M., Lahr C. A., Sanchez-Herrero A., Meinert C., Shokoohmand A., Pollock P. M., Hutmacher D. W., Shafiee A., McGovern J. A. Humanized bone facilitates prostate cancer metastasis and recapitulates therapeutic effects of zoledronic acid in vivo. Bone Research. 2019; 7: 31. https://doi.org/10.1038/s41413-020-0092-5Landgraf M., Lahr C. A., Sanchez-Herrero A., Meinert C., Shokoohmand A., Pollock P. M., Hutmacher D. W., Shafiee A., McGovern J. A. Humanized bone facilitates prostate cancer metastasis and recapitulates therapeutic effects of zoledronic acid in vivo. Bone Research. 2019; 7: 31. https://doi.org/10.1038/s41413-020-0092-5Mandal C. C. Cancer and Bone Metastasis. Front. Endocrinol. 2019; 10: 852. https://doi.org/10.3389/fendo.2019.00852Mandal C. C. Cancer and Bone Metastasis. Front. Endocrinol. 2019; 10: 852. https://doi.org/10.3389/fendo.2019.00852Zhang L., Gong Z. Clinical Characteristics and Prognostic Factors in Bone Metastases from Lung Cancer. Med Sci Monit. 2017; 23: 4087-4094. https://doi.org/10.12659/MSM.902971Zhang L., Gong Z. Clinical Characteristics and Prognostic Factors in Bone Metastases from Lung Cancer. Med Sci Monit. 2017; 23: 4087-4094. https://doi.org/10.12659/MSM.902971Fornetti J., Welm A. L., Stewart S. A. Understanding the Bone in Cancer Metastasis. JBMR. 2018; 33 (12): 2099-2113. https://doi.org/10.1002/jbmr.3618Fornetti J., Welm A. L., Stewart S. A. Understanding the Bone in Cancer Metastasis. JBMR. 2018; 33 (12): 2099-2113. https://doi.org/10.1002/jbmr.3618Xie F., Ling L., van Dam H. et al. TGF-β signaling in cancer metastasis. Acta Biochim Biophys Sin (Shanghai). 2018; 50 (1): 121-132. https://doi.org/10.1093/abbs/gmx123Xie F., Ling L., van Dam H. et al. TGF-β signaling in cancer metastasis. Acta Biochim Biophys Sin (Shanghai). 2018; 50 (1): 121-132. https://doi.org/10.1093/abbs/gmx123Karlsson T., Sundar R., Widmark A. Osteoblast-derived factors promote metastatic potential in human prostate cancer cells, in part via non-canonical transforming growth factor β (TGF-β) signaling. Prostate. 2018; 78 (6): 446-456. https://doi.org/10.1002/pros.23489Karlsson T., Sundar R., Widmark A. Osteoblast-derived factors promote metastatic potential in human prostate cancer cells, in part via non-canonical transforming growth factor β (TGF-β) signaling. Prostate. 2018; 78 (6): 446-456. https://doi.org/10.1002/pros.23489Kruger T.E., Miller A.H., Godwin A.K. et al. Bone Sialoprotein and Osteopontin in Bone Metastasis of Osteotropic Cancers. Crit Rev Oncol Hematol. 2014; 89 (2): 330-341. https://doi.org/10.1016/j.critrevonc.2013.08.013Kruger T.E., Miller A.H., Godwin A.K. et al. Bone Sialoprotein and Osteopontin in Bone Metastasis of Osteotropic Cancers. Crit Rev Oncol Hematol. 2014; 89 (2): 330-341. https://doi.org/10.1016/j.critrevonc.2013.08.013Wieczorek E., Jablonska E., Wasowicz W. et al. Matrix metalloproteinases and genetic mouse models in cancer research: a mini-review. Tumour Biol. 2015; 36 (1): 163-175. https://doi.org/10.1007/s13277-014-2747-6Wieczorek E., Jablonska E., Wasowicz W. et al. Matrix metalloproteinases and genetic mouse models in cancer research: a mini-review. Tumour Biol. 2015; 36 (1): 163-175. https://doi.org/10.1007/s13277-014-2747-6Zhao H., Chen Q., Alam A., Cui J., Suen K. C. et al. The role of osteopontin in the progression of solid organ tumour. Cell Death Dis. 2018; 9 (3): 356. https://doi.org/10.1038/s41419-018-0391-6Zhao H., Chen Q., Alam A., Cui J., Suen K. C. et al. The role of osteopontin in the progression of solid organ tumour. Cell Death Dis. 2018; 9 (3): 356. https://doi.org/10.1038/s41419-018-0391-6Infante M., Fabi A., Cognetti F. et al. RANKL/RANK/OPG system beyond bone remodeling: involvement in breast cancer and clinical perspectives. J Exp Clin Cancer Res. 2019; 38: 12. https://doi.org/10.1186/s13046-018-1001-2Infante M., Fabi A., Cognetti F. et al. RANKL/RANK/OPG system beyond bone remodeling: involvement in breast cancer and clinical perspectives. J Exp Clin Cancer Res. 2019; 38: 12. https://doi.org/10.1186/s13046-018-1001-2Li X., Liu Y., Wu B. et al. Potential role of the OPG/RANK/RANKL axis in prostate cancer invasion and bone metastasis. Oncol Rep. 2014; 32 (6): 2605-11. https://doi.org/10.3892/or.2014.3511Li X., Liu Y., Wu B. et al. Potential role of the OPG/RANK/RANKL axis in prostate cancer invasion and bone metastasis. Oncol Rep. 2014; 32 (6): 2605-11. https://doi.org/10.3892/or.2014.3511Brown N. E., Sullivan C., Waltz S. E. Therapeutic Considerations for Ron Receptor Expression in Prostate Cancer. EMS Cancer Sci J. 2018; 1 (1): 003.Brown N. E., Sullivan C., Waltz S. E. Therapeutic Considerations for Ron Receptor Expression in Prostate Cancer. EMS Cancer Sci J. 2018; 1 (1): 003.Brown N.E., Paluch A.M., Nashu M.A. Tumor Cell Autonomous RON Receptor Expression Promotes Prostate Cancer Growth Under Conditions of Androgen Deprivation. Neoplasia. 2018; 20 (9): 917-929. https://doi.org/10.1016/j.neo.2018.07.003Brown N.E., Paluch A.M., Nashu M.A. Tumor Cell Autonomous RON Receptor Expression Promotes Prostate Cancer Growth Under Conditions of Androgen Deprivation. Neoplasia. 2018; 20 (9): 917-929. https://doi.org/10.1016/j.neo.2018.07.003Andrade K., Fornetti J., Ling Zhao L. et al. RON kinase: A target for treatment of cancer-induced bone destruction and osteoporosis. Sci Transl Med. 2017; 9 (374): eaai9338. https://doi.org/10.1126/scitranslmed.aai9338Andrade K., Fornetti J., Ling Zhao L. et al. RON kinase: A target for treatment of cancer-induced bone destruction and osteoporosis. Sci Transl Med. 2017; 9 (374): eaai9338. https://doi.org/10.1126/scitranslmed.aai9338Huang D. C., Yang X. F., Ochietti B. et al. Parathyroid Hormone-Related Protein: Potential Therapeutic Target for Melanoma Invasion and Metastasis. Endocrinology. 2014; 155 (10):3739-3749. https://doi.org/10.1210/en.2013-1803Huang D. C., Yang X. F., Ochietti B. et al. Parathyroid Hormone-Related Protein: Potential Therapeutic Target for Melanoma Invasion and Metastasis. Endocrinology. 2014; 155 (10):3739-3749. https://doi.org/10.1210/en.2013-1803Frieling J. S., Lynch C. C. Proteolytic Regulation of Parathyroid Hormone-Related Protein: Functional Implications for Skeletal Malignancy. Int J Mol Sci. 2019; 20 (11): 2814. https://doi.org/10.3390/ijms20112814Frieling J. S., Lynch C. C. Proteolytic Regulation of Parathyroid Hormone-Related Protein: Functional Implications for Skeletal Malignancy. Int J Mol Sci. 2019; 20 (11): 2814. https://doi.org/10.3390/ijms20112814Zhao F., Wang J., Chen M. et al. Sites of synchronous distant metastases and prognosis in prostate cancer patients with bone metastases at initial diagnosis: a population-based study of 16,643 patients. Clin Transl Med. 2019; 8: 30. https://doi.org/10.1186/s40169-019-0247-4Zhao F., Wang J., Chen M. et al. Sites of synchronous distant metastases and prognosis in prostate cancer patients with bone metastases at initial diagnosis: a population-based study of 16,643 patients. Clin Transl Med. 2019; 8: 30. https://doi.org/10.1186/s40169-019-0247-4Frieling J.S., Basanta D., Lynch C.C. Current and Emerging Therapies for Bone Metastatic Castration-Resistant Prostate Cancer. Cancer Control. 2015; 22 (1): 109-120. https://doi.org/10.1177/107327481502200114Frieling J.S., Basanta D., Lynch C.C. Current and Emerging Therapies for Bone Metastatic Castration-Resistant Prostate Cancer. Cancer Control. 2015; 22 (1): 109-120. https://doi.org/10.1177/107327481502200114Спирина Л. В., Горбунов А. К., Кондакова И. В., Усынин Е. А., Слонимская Е. М. Связь молекулярных маркеров с эффективностью и временем ответа на андрогендепривационную терапию у больных раком предстательной железы. Успехи молекулярной онкологии. 2019; 6 (1): 44-48. [Spirina L. V., Gorbunov A. K., Kondakova I. V., Usynin E. A., Slonimskaya E. M. Association between the molecular markers, effect and time of response to the androgen-deprivation therapy in patients with prostate cancer. Advances in Molecular Oncology. 2019; 6 (1): 44-48. (In Russ.)] https://doi.org/10.17650/2313-805X-2019-6-1-44-48Спирина Л. В., Горбунов А. К., Кондакова И. В., Усынин Е. А., Слонимская Е. М. Связь молекулярных маркеров с эффективностью и временем ответа на андрогендепривационную терапию у больных раком предстательной железы. Успехи молекулярной онкологии. 2019; 6 (1): 44-48. [Spirina L. V., Gorbunov A. K., Kondakova I. V., Usynin E. A., Slonimskaya E. M. Association between the molecular markers, effect and time of response to the androgen-deprivation therapy in patients with prostate cancer. Advances in Molecular Oncology. 2019; 6 (1): 44-48. (In Russ.)] https://doi.org/10.17650/2313-805X-2019-6-1-44-48Ohtaka M., Kawahara T, Mochizuki T., Takamoto D. RANK/RANKL expression in prostate cancer. Int J Surg Case Rep. 2017; 30: 106-107. https://doi.org/10.1016/j.ijscr.2016.11.042Ohtaka M., Kawahara T, Mochizuki T., Takamoto D. RANK/RANKL expression in prostate cancer. Int J Surg Case Rep. 2017; 30: 106-107. https://doi.org/10.1016/j.ijscr.2016.11.042Christoph F., König F., Lebentrau S. et al. RANKL/RANK/OPG cytokine receptor system: mRNA expression pattern in BPH, primary and metastatic prostate cancer disease. World J Urol. 2018; 36 (2): 187-192. https://doi.org/10.1007/s00345-017-2145-yChristoph F., König F., Lebentrau S. et al. RANKL/RANK/OPG cytokine receptor system: mRNA expression pattern in BPH, primary and metastatic prostate cancer disease. World J Urol. 2018; 36 (2): 187-192. https://doi.org/10.1007/s00345-017-2145-yHandy C. E., Antonarakis E. S. Sipuleucel-T for the treatment of prostate cancer: novel insights and future directions. Future Oncol. 2018; 14 (10): 907-917. https://doi.org/doi:10.2217/fon-2017-0531Handy C. E., Antonarakis E. S. Sipuleucel-T for the treatment of prostate cancer: novel insights and future directions. Future Oncol. 2018; 14 (10): 907-917. https://doi.org/doi:10.2217/fon-2017-0531Dores G. M., Bryant-Genevier M., Perez-Vilar S. Adverse Events Associated With the Use of Sipuleucel-T Reported to the US Food and Drug Administration’s Adverse Event Reporting System, 2010-2017. JAMA Netw Open. 2019; 2 (8): e199249. https://doi.org/10.1001/jamanetworkopen.2019.9249Dores G. M., Bryant-Genevier M., Perez-Vilar S. Adverse Events Associated With the Use of Sipuleucel-T Reported to the US Food and Drug Administration’s Adverse Event Reporting System, 2010-2017. JAMA Netw Open. 2019; 2 (8): e199249. https://doi.org/10.1001/jamanetworkopen.2019.9249Arciero C. A., Guo Y., Jiang R., Behera M. ER+/HER 2+ Breast Cancer Has Different Metastatic Patterns and Better Survival Than ER-/HER 2+ Breast Cancer. Clin Breast Cancer. 2019; 19 (4): 236-245. https://doi.org/10.1016/j.clbc.2019.02.001.Arciero C. A., Guo Y., Jiang R., Behera M. ER+/HER 2+ Breast Cancer Has Different Metastatic Patterns and Better Survival Than ER-/HER 2+ Breast Cancer. Clin Breast Cancer. 2019; 19 (4): 236-245. https://doi.org/10.1016/j.clbc.2019.02.001.Bado I., Gugala Z., Fuqua S.A.W., Zhang X.H.-F. Estrogen Receptors in Breast and Bone: from Virtue of Remodeling to Vileness of Metastasis. Oncogene. 2017; 36 (32): 4527-4537. https://doi.org/10.1038/onc.2017.94Bado I., Gugala Z., Fuqua S.A.W., Zhang X.H.-F. Estrogen Receptors in Breast and Bone: from Virtue of Remodeling to Vileness of Metastasis. Oncogene. 2017; 36 (32): 4527-4537. https://doi.org/10.1038/onc.2017.94Chen S. C., Kuo P. L. Bone Metastasis from Renal Cell Carcinoma. Int J Mol Sci. 2016; 17 (6): 987. https://doi.org/10.3390/ijms17060987Chen S. C., Kuo P. L. Bone Metastasis from Renal Cell Carcinoma. Int J Mol Sci. 2016; 17 (6): 987. https://doi.org/10.3390/ijms17060987Emily C. L., Wong A. K. Does Bone-targeted Therapy Benefit Patients with Metastatic Renal Cell Carcinoma? Transl Oncol. 2020; 13 (2): 241-244. https://doi.org/10.1016/j.tranon.2019.10.009Emily C. L., Wong A. K. Does Bone-targeted Therapy Benefit Patients with Metastatic Renal Cell Carcinoma? Transl Oncol. 2020; 13 (2): 241-244. https://doi.org/10.1016/j.tranon.2019.10.009Haber T., Jöckel E., Roos F. C. Bone Metastasis in Renal Cell Carcinoma is Preprogrammed in the Primary Tumor and Caused by AKT and Integrin α5 Signaling. J Urol. 2015; 194 (2): 539-546. https://doi.org/10.1016/j.juro.2015.01.079Haber T., Jöckel E., Roos F. C. Bone Metastasis in Renal Cell Carcinoma is Preprogrammed in the Primary Tumor and Caused by AKT and Integrin α5 Signaling. J Urol. 2015; 194 (2): 539-546. https://doi.org/10.1016/j.juro.2015.01.079Liu W., Bian C., Liang Y., Chen Q. et al. CX3CL1: a potential chemokine widely involved in the process spinal metastases. Oncotarget. 2017; 8 (9): 15213-15219. https://doi.org/10.18632/oncotarget.14773Liu W., Bian C., Liang Y., Chen Q. et al. CX3CL1: a potential chemokine widely involved in the process spinal metastases. Oncotarget. 2017; 8 (9): 15213-15219. https://doi.org/10.18632/oncotarget.14773Yao X., Qi L., Chen X., Du J., Zhang Z., Liu S. Expression of CX3CR1 associates with cellular migration, metastasis, and prognosis in human clear cell renal cell carcinoma. Urol Oncol. 2014; 32: 162-170. https://doi.org/10.1016/j.urolonc.2012.12.006Yao X., Qi L., Chen X., Du J., Zhang Z., Liu S. Expression of CX3CR1 associates with cellular migration, metastasis, and prognosis in human clear cell renal cell carcinoma. Urol Oncol. 2014; 32: 162-170. https://doi.org/10.1016/j.urolonc.2012.12.006Lerano C., Santagata S., Napolitano M., Guardia F. et al. CXCR4 and CXCR7 transduce through mTOR in human renal cancer cells. Cell Death Dis. 2014; 5 (7): e1310. https://doi.org/10.1038/cddis.2014.269Lerano C., Santagata S., Napolitano M., Guardia F. et al. CXCR4 and CXCR7 transduce through mTOR in human renal cancer cells. Cell Death Dis. 2014; 5 (7): e1310. https://doi.org/10.1038/cddis.2014.269Guan Z., Li C., Fan J., He D., Li L. Androgen receptor (AR) signaling promotes RCC progression via increased endothelial cell proliferation and recruitment by modulating AKT → NF-κB → CXCL5 signaling. Sci Rep. 2016; 6: 37085. https://doi.org/10.1038/srep37085Guan Z., Li C., Fan J., He D., Li L. Androgen receptor (AR) signaling promotes RCC progression via increased endothelial cell proliferation and recruitment by modulating AKT → NF-κB → CXCL5 signaling. Sci Rep. 2016; 6: 37085. https://doi.org/10.1038/srep37085Zeng Q., Sun S., Li Y. et al. Identification of Therapeutic Targets and Prognostic Biomarkers Among CXC Chemokines in the Renal Cell Carcinoma Microenvironment. Front Oncol. 2019; 9: 1555. https://doi.org/10.3389/fonc.2019.01555Zeng Q., Sun S., Li Y. et al. Identification of Therapeutic Targets and Prognostic Biomarkers Among CXC Chemokines in the Renal Cell Carcinoma Microenvironment. Front Oncol. 2019; 9: 1555. https://doi.org/10.3389/fonc.2019.01555Venkatesan P. Intermittent sunitinib for metastatic renal cell carcinoma. The Lancet Oncology. 2017; 18 (3), e139. https://doi.org/10.1016/S1470-2045(17)30082-7Venkatesan P. Intermittent sunitinib for metastatic renal cell carcinoma. The Lancet Oncology. 2017; 18 (3), e139. https://doi.org/10.1016/S1470-2045(17)30082-7Varkaris A., Xu W., Davis R. B. et al. Combining Immune Checkpoint and VEGFR Inhibition in Favorable Risk and Elderly Patients with Metastatic Renal Cell Carcinoma. Clin Genitourin Cancer. 2019. pii: S 1558-7673(19)30367-2.Varkaris A., Xu W., Davis R. B. et al. Combining Immune Checkpoint and VEGFR Inhibition in Favorable Risk and Elderly Patients with Metastatic Renal Cell Carcinoma. Clin Genitourin Cancer. 2019. pii: S 1558-7673(19)30367-2.Cihan Y. B. Effectiveness of pazopanib and SBRT in metastatic renal cell carcinoma. World J Urol. 2018; 36 (11): 1797-1798. https://doi.org/10.1007/s00345-018-2323-6Cihan Y. B. Effectiveness of pazopanib and SBRT in metastatic renal cell carcinoma. World J Urol. 2018; 36 (11): 1797-1798. https://doi.org/10.1007/s00345-018-2323-6Grimm M. O., Leucht K., Grünwald V. et al. New First Line Treatment Options of Clear Cell Renal Cell Cancer Patients with PD-1 or PD-L1 Immune-Checkpoint Inhibitor-Based Combination Therapies. Clin Med. 2020; 9 (2). pii: E 565. https://doi.org/10.3390/jcm9020565Grimm M. O., Leucht K., Grünwald V. et al. New First Line Treatment Options of Clear Cell Renal Cell Cancer Patients with PD-1 or PD-L1 Immune-Checkpoint Inhibitor-Based Combination Therapies. Clin Med. 2020; 9 (2). pii: E 565. https://doi.org/10.3390/jcm9020565Алексеев Б.Я., Шевчук И.М., Каприн А.Д. Возможности индивидуального подхода в выборе 2-й линии таргетной терапии при метастатическом почечно-клеточном раке. Онкоурология. 2018; 2: 68-78. [Alekseev B. Y., Shevchuk I. M., Kaprin A. D. Individual approach in choosing second-line targeted therapy for metastatic renal cell carcinoma. Cancer Urology. 2018; 14 (2): 68-78. (In Russ.)] https://doi.org/10.17650/1726-9776-2018-14-2-68-78Алексеев Б.Я., Шевчук И.М., Каприн А.Д. Возможности индивидуального подхода в выборе 2-й линии таргетной терапии при метастатическом почечно-клеточном раке. Онкоурология. 2018; 2: 68-78. [Alekseev B. Y., Shevchuk I. M., Kaprin A. D. Individual approach in choosing second-line targeted therapy for metastatic renal cell carcinoma. Cancer Urology. 2018; 14 (2): 68-78. (In Russ.)] https://doi.org/10.17650/1726-9776-2018-14-2-68-78

The authors declare that there are no conflicts of interest present.